Evidence map›Paper›PMID 36412238›Full record

ArticleClinical pharmacology and therapeutics2023

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Fabienne Thomas, Manon Launay, Jérôme Guitton, Marie-Anne Loriot, Jean-Christophe Boyer, Vincent Haufroid, Marie-Christine Etienne-Grimaldi, Bernard Royer, GPCO-UNICANCER Group

Open access · greenAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Fabienne ThomasCentre de Recherches en Cancérologie, Inserm, CNRS, Université Toulouse III-Paul Sabatier and IUCT-Oncopole, Toulouse, France.ORCID 0000-0001-9886-412X
Manon LaunayPlateau de Biologie, CHU Saint Etienne, Saint Etienne, France.ORCID 0000-0003-3113-7301
Jérôme GuittonLaboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, France.
Marie-Anne LoriotDepartment of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
Jean-Christophe BoyerBiochemistry Laboratory, Carrémeau University Hospital, Nîmes, France.
Vincent HaufroidDepartment of Clinical Chemistry, Cliniques Universitaires Saint-Luc and Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.ORCID 0000-0001-5040-9806
Marie-Christine Etienne-GrimaldiOncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.
Bernard RoyerLaboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France.
GPCO-UNICANCER Group
Inserm · FRCentre Antoine Lacassagne · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre National de la Recherche Scientifique · FRCliniques Universitaires Saint-Luc · BELaboratoire de Biologie Structurale de la Cellule · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dihydropyrimidine Dehydrogenase DeficiencyUracilDihydrouracil Dehydrogenase (NADP)FluorouracilHumansDihydrouracil Dehydrogenase (NADP)FluorouracilUracil

Identifiers

PMID36412238
OpenAlexW4309548095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.